pathologic _ N age _ at _ collection _ years mean _ per _ monocyte mean _ per _ neutrophil sample _ oct _ embeddedprior _ dx pathologic _ M sample _ initial _ weight portion _ weight primary _ diagnosis tissue _ or _ organ _ of _ originstage her2 _ immunohistochemistry _ level _ result pathologic _ stage breast _ carcinoma _ progesterone _ receptor _ status mean _ per _ necrosis tumor _ stage menopause _ status breast _ carcinoma _ estrogen _ receptor _ status mean _ per _ normal _ cells mean _ per _ lymphocyteraceethnicity tissue _ retrospective _ collection _ indicator tissue _ prospective _ collection _ indicator lab _ proc _ her2 _ neu _ immunohistochemistry _ receptor _ status pos _ lymph _ fraction morphologyportion _ year histological _ type pathologic _ T anatomic _ neoplasm _ subdivision grouped _ morphology RNA _ abs _ ratio RNA _ analyte _ conc RNA _ aliquot _ conc mean _ per _ tumor _ nuclei mean _ per _ tumor _ cells mean _ per _ stromal _ cells phenotype PC1 PC2 20 40 60 −log10 ( adj−p ) BRCA ethnicity pathologic _ N presence _ of _ pathological _ nodal _ extracapsular _ spread longest _ dimensionclinical _ T race primary _ diagnosis tissue _ or _ organ _ of _ origin tissue _ retrospective _ collection _ indicator tissue _ prospective _ collection _ indicatorclinical _ M clinical _ stage shortest _ dimension intermediate _ dimension portion _ weight cigarettes _ per _ day mean _ per _ stromal _ cells mean _ per _ neutrophil mean _ per _ necrosis number _ pack _ years _ smoked mean _ per _ monocytelaterality mean _ per _ tumor _ nuclei tobacco _ smoking _ historygender alcohol _ history morphology histological _ type pathologic _ T clinical _ N anatomic _ neoplasm _ subdivision neoplasm _ histologic _ grade perineural _ invasion _ present lymphovascular _ invasion _ present alcohol _ history _ documented age _ at _ diagnosis . days . mean _ per _ tumor _ cells mean _ per _ normal _ cells tumor _ stagestage pathologic _ stage RNA _ abs _ ratio mean _ per _ lymphocyte pos _ lymph _ fraction aliquot _ source _ center RNA _ analyte _ conc RNA _ aliquot _ conc portion _ year phenotype PC1 PC2 510152025 −log10 ( adj−p ) HNSC lateralityethnicity mean _ per _ tumor _ cells pathologic _ N mean _ per _ normal _ cells hemoglobin _ result platelet _ qualitative _ result shortest _ dimension longest _ dimension serum _ calcium _ result white _ cell _ count _ result intermediate _ dimension age _ at _ diagnosis . days . mean _ per _ stromal _ cells pathologic _ M portion _ weightgender morphology mean _ per _ tumor _ nucleirace aliquot _ source _ center tumor _ stage portion _ yearstage tissue _ retrospective _ collection _ indicator tissue _ prospective _ collection _ indicator pathologic _ stage neoplasm _ histologic _ grade RNA _ abs _ ratio RNA _ analyte _ conc RNA _ aliquot _ conc mean _ per _ necrosis pathologic _ T phenotype PC1 PC2 10 20 30 40 −log10 ( adj−p ) KIRC aliquot _ source _ center age _ at _ diagnosis . days . cigarettes _ per _ day primary _ diagnosis pathologic _ M intermediate _ dimension RNA _ analyte _ conc RNA _ aliquot _ conc mean _ per _ normal _ cells number _ pack _ years _ smoked histological _ type anatomic _ neoplasm _ subdivision longest _ dimension tissue _ or _ organ _ of _ origin tobacco _ smoking _ history morphology shortest _ dimension RNA _ abs _ ratiostagerace tumor _ stage pathologic _ stage mean _ per _ necrosis mean _ per _ tumor _ cells genderethnicity portion _ year tissue _ retrospective _ collection _ indicator tissue _ prospective _ collection _ indicator pathologic _ T pathologic _ N portion _ weight mean _ per _ tumor _ nuclei mean _ per _ stromal _ cells phenotype PC1 PC2 25 50 75 100 −log10 ( adj−p ) LUAD mean _ per _ lymphocyte tobacco _ smoking _ history shortest _ dimensionmorphology anatomic _ neoplasm _ subdivision mean _ per _ tumor _ nucleistage primary _ diagnosis tissue _ or _ organ _ of _ origin mean _ per _ tumor _ cells mean _ per _ stromal _ cells pathologic _ T intermediate _ dimensiongenderethnicity histological _ type age _ at _ diagnosis . days . mean _ per _ normal _ cells mean _ per _ necrosis pathologic _ N race cigarettes _ per _ day number _ pack _ years _ smoked pathologic _ M tissue _ retrospective _ collection _ indicator tissue _ prospective _ collection _ indicator longest _ dimension pathologic _ stage tumor _ stage RNA _ abs _ ratio RNA _ analyte _ conc RNA _ aliquot _ conc aliquot _ source _ center portion _ weight portion _ year phenotype PC1 PC2 10 20 30 −log10 ( adj−p ) LUSC primary _ diagnosis tissue _ or _ organ _ of _ origin portion _ year tumor _ tissue _ site mean _ per _ tumor _ cells aliquot _ source _ center morphology intermediate _ dimension clinical _ stage shortest _ dimension age _ at _ diagnosis . days . mean _ per _ normal _ cellsrace RNA _ abs _ ratio mean _ per _ tumor _ nuclei neoplasm _ histologic _ grade longest _ dimension mean _ per _ necrosis anatomic _ neoplasm _ subdivision RNA _ analyte _ conc RNA _ aliquot _ conc mean _ per _ stromal _ cells portion _ weight phenotype PC1 PC2 10 20 −log10 ( adj−p ) OV aliquot _ source _ center primary _ diagnosis tissue _ retrospective _ collection _ indicator tissue _ prospective _ collection _ indicator portion _ weight mean _ per _ tumor _ nuclei psa _ value pos _ lymph _ fraction RNA _ analyte _ conc RNA _ aliquot _ conc mean _ per _ tumor _ cells mean _ per _ stromal _ cells mean _ per _ monocyte sample _ oct _ embeddedmorphologyportion _ year pathologic _ N clinical _ T laterality zone _ of _ origin tumor _ level sample _ initial _ weight RNA _ abs _ ratio age _ at _ collection _ years mean _ per _ neutrophil mean _ per _ necrosis histological _ type clinical _ M secondary _ pattern mean _ per _ lymphocyte mean _ per _ normal _ cells pathologic _ T primary _ pattern gleason _ score phenotype PC1 PC2 1020304050 −log10 ( adj−p ) PRAD Fig . S1 . Differential editing not confounded by metadata . Heatmaps of significance ( log10 - transformed adjusted p - values ) of correlations between the top two principal components and E / M phenotype among metadata fields in each cancer type . Darker color indicates smaller p - value and stronger association . BRCA LUAD LUSC PRAD OV KIRC HNSC a ll h y p e r e d i t e d h y p o e d i t e d a ll h y p e r e d i t e d h y p o e d i t e d a ll h y p e r e d i t e d h y p o e d i t e d a ll h y p e r e d i t e d h y p o e d i t e d a ll h y p e r e d i t e d h y p o e d i t e d a ll h y p e r e d i t e d h y p o e d i t e d a ll h y p e r e d i t e d h y p o e d i t e d mitochondrial electron transport , NADH to ubiquinone cell surface receptor signaling pathway chemotaxis fatty acid biosynthetic process cellular lipid metabolic process one−carbon metabolic process n ucleobase−containing compound metabolic process mRNA metabolic process RNA metabolic process glycosaminoglycan metabolic process glycosphingolipid metabolic process sphingolipid metabolic process xenobiotic metabolic process small molecule metabolic process cellular protein metabolic process w ater−solu ble vitamin metabolic process vitamin metabolic process cellular metabolic process ion transport retrograde v esicle−mediated t ransport , Golgi to ER v esicle−mediated t ransport SRP−dependent cot ranslational protein targeting to membrane intracellular protein transport protein transport positive regulation of catalytic activity protein catabolic process proteolysis protein stabilization peptidyl−se rine phosphorylation protein autophosphorylation protein homooligomerization positive regulation of protein ubiquitination protein autoubiquitination protein polyubiquitination protein glycosylation cellular protein modification process translational termination translational elongation translational initiation positive regulation of translationtranslation gene expression rRNA processing n uclear−t ranscribed mRNA catabolic process , nonsense−mediated dec ay regulation of transcr iption , DNA−templated transcr iption , DNA−templated CENP−A containing nucleosome assembly nucleosome assembly DNA replication stem cell population maintenance n ucleotide− excision repair telomere maintenance response to UV cellular response to hypoxia mitotic cell cycle cytokine−mediated signaling path way antigen processing and presentation of exogenous peptide antigen via MHC class II antigen processing and presentation of peptide antigen via MHC class I positiv e regulation of I−kappaB kinase / NF−kappaB signaling regulation of apoptotic process apoptotic signaling pathway negative regulation of viral genome replication viral transcriptionviral life cycle viral process response to virus positive regulation of defense response to virus by host defense response to virus defense response to bacterium defense response negative regulation of type I interferon production positive regulation of type I interferon production innate immune response immune response −log10 ( q− value ) 5 101520 25 all hyperedited hypoedited Fig . S2 . Gene ontology enrichment among differentially edited genes . Significance of enrichment of gene ontology ( GO ) terms among all differentially edited genes ( blue ) , only hyperedited genes ( green ) or only hypoedited genes ( pink ) of each cancer type . Point size represents the statistical significance of enrichment ( log10 - transformed adjusted p - value ) . Terms significantly enriched in at least two cancer types are shown . For cancer types with a global hyperediting trend in M tumors , GO enrichment among hyperedited genes is similar to that among all differentially edited genes . Likewise , for cancer types with a hypoediting trend ( BRCA and OV ) , enrichment among hypoedited genes is similar to that among all differentially edited genes . −4 0 4 8 −4 0 4 tSNE 1 t S N E 2 T cell Cancer Fibro Myeloid EC Epi Alveolar B cell C D 3 D E P C A M C 1 R C O L 1 A 1 C O L 1 A 2 D C N C D 6 8 F C G R 3 A L Y Z M A R C O C D H 5 C L D N 5 F L T 1 R A M P 2 C A P S P I F O S N T N T M E M 1 9 0 A Q P 4 C L D N 1 8 F O L R 1 P E B P 4 C D 7 9 A 0 1 2 3 0123 4 01 2 3 4 2 . 0 2 . 5 3 . 0 3 . 5 0 1 2 3 0 1 2 3 4 01 2 3 4 2 . 0 2 . 5 3 . 0 3 . 5 l og1 0 ( C P M ) Cell Type Alveolar B cell EC Epi Fibro Mast Myeloid T cell Cancer Signature Matrix T cell Cancer Fibro Myeloid EC Epi Alveolar B cell C D 3 D T R A C T R B C 2 E P C A M C 1 R C O L 1 A 1 C O L 1 A 2 D C N C D 6 8 F C G R 3 A L Y Z M A R C O C D H 5 C L D N 5 F L T 1 R A M P 2 C A P S P I F O S N T N T M E M 1 9 0 A Q P 4 C L D N 1 8 F O L R 1 P E B P 4 C D 7 9 A I G H G 3 I G K C I G L C 3 0123 4 5 −2 0 2 0 1 2 3 0 . 5 1 . 0 1 . 5 2 . 0 −1 0 1 2 −1 0123 −1 0 1 2 1 . 0 1 . 5 2 . 0 2 . 5 3 . 0 l og10 ( R PK M ) Pooled Cells D B −50 −25 0 25 50 −50 −25 0 25 tSNE 1 t S N E 2 A Cluster Matching cell types Matching markers Cluster Matching cell types Matching markers C T cell Myeloid Cancer B cell Fibroblast Endothelial Cell Alveolar ; Epi ; Cancer Cancer Cancer B cell Mast EpithelialAlveolar NA NA Cell Type Count CD3D LYZ , MARCO , CD68 , FCGR3A EPCAM CD79A COL1A1 , DCN , COL1A2 , C1R CD79A EPCAM EPCAM CLDN5 , FLT1 , CDH5 , RAMP2 TPSAB1 , CPA3 , HPGDS , KIT FOLR1 ; CAPS , TMEM190 , PIFO , SNTN ; EPCAM SFTPB CAPS , TMEM190 , SNTN T cellCancer Myeloid B cell Fibroblast Endothelial Cell Mast Epithelial Alveolar 16354 6526 4063 2770 998 771 285 62 29 Fig . S3 . Clustering of single cells from three lung cancer tumors . A . TSNE projection of cells based on expression profiles , with color indicating cluster identity ( left ) . Cell types were assigned to clusters by matching differentially expressed genes of clusters to known cell type markers ( right ) . B . TSNE projection of only cells from cluster 10 to further refine cell type assignment ( left ) . Similar to A , cell types were labeled using differentially expressed genes that matched cell type markers ( right ) . C . Counts of cells for each cell type after 2 rounds of clustering and cell type assignment ( A and B ) . D . Log2 - transformed expression values of marker genes across cell types . Signature matrix on the left indicates expression values assigned for each cell type by CIBERSORTx . On the right , Pooled Cells indicate that expression values were calculated from pooling reads from cells of the same type together . l og10 ( C P M ) l og10 ( C P M ) l og10 ( C P M ) l og10 ( R PK M ) l og10 ( R PK M ) l og10 ( R PK M ) ns ns * * * 0 10000 20000 30000 40000 s a m p l e3a s a m p l e3b s a m p l e3 c s a m p l e4b s a m p l e4 c s a m p l e4d s a m p l e5a s a m p l e5b s a m p l e5 c U M I c oun t phenotype E M ns 0 10000 20000 30000 40000 U M I c oun t ns 2000 4000 6000 G ene c oun t ns 0 . 0 2 . 5 5 . 0 7 . 5 % M i t o ns * * ns 0 . 0 2 . 5 5 . 0 7 . 5 s a m p l e3a s a m p l e3b s a m p l e3 c s a m p l e4b s a m p l e4 c s a m p l e4d s a m p l e5a s a m p l e5b s a m p l e5 c % M i t o ns ns * * * 2000 4000 6000 s a m p l e3a s a m p l e3b s a m p l e3 c s a m p l e4b s a m p l e4 c s a m p l e4d s a m p l e5a s a m p l e5b s a m p l e5 c G ene c oun t E E E M M M A B C D E F Fig . S4 . E and M assignment of single cells not confounded by metadata . Comparison between E and M cells altogether ( top ) and within each tumor sample ( bottom ) of metadata fields : UMI count ( A - B ) , gene count ( C - D ) , and percent of reads mapping to the mitochondrial genome ( E - F ) . Metadata values were compared by Mann Whitney U tests , and significance of p - values are shown . ns : p > 0 . 05 , * p ≤ 0 . 05 , * * p ≤ 0 . 01 . −0 . 0082 −0 . 0089 −0 . 02 −0 . 014 0 . 02 0 . 0032 0 . 021 −0 . 011 −0 . 007 −0 . 0011 −0 . 019 −0 . 029 −0 . 019 −0 . 0082 −0 . 00036 0 . 01 0 . 043 0 . 012 LUAD LUSC A C007246 . 3 chr2 : 39701980 ARL16 chr17 : 79648370 BPNT1 chr1 : 220231254 MRPS16 chr10 : 75008797 MRPS16 chr10 : 75008815 MRPS16 chr10 : 75008817 MRPS16 chr10 : 75008841 RHO A chr3 : 49397323 RP11−792A8 . 4 chr7 : 66205084 p < 0 . 05 Fig . S5 . LUAD and LUSC tumor editing differences of differential sites identified from single cell RNA - seq analysis . For each editing site , the difference in mean editing levels between M and E tumors ( M - E ) in each cancer type is listed . Green highlight indicates Wilcoxon p - value < 0 . 05 . ns sig LUAD LUSC sigADAR1 redADAR1 sigADAR2 redADAR2 sigBoth redBoth Remain A C B ADAR1 ADAR2 c on t r o l A D A R 1 K D A D A R 2 K D D oub l e K D c on t r o l A D A R 1 K D A D A R 2 K D D oub l e K D 1 . 5 2 . 0 2 . 5 3 . 0 3 . 5 40 80 120 160 T P M condition controlADAR1 KD ADAR2 KD Double KD n = 4 n = 12370 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 Control mean editing level A D A R 1 K D m e an ed i t i ng l e v e l ADAR1 KD vs Control n = 106 n = 312 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 Control mean editing level A D A R 2 K D m ean ed i t i ng l e v e l ADAR2 KD vs Control n = 6 n = 11184 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 Control mean editing level D oub l e K D m ean ed i t i ng l e v e l Double KD vs Control n = 48 n = 44 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 ADAR1 KD mean editing level D oub l e K D m ean ed i t i ng l e v e l Double KD vs ADAR1 KD n = 1 n = 9918 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 0 . 00 0 . 25 0 . 50 0 . 75 1 . 00 ADAR2 KD mean editing level D oub l e K D m ean ed i t i ng l e v e l Double KD vs ADAR2 KD Fig . S6 . Altered editing upon knockdown of ADAR1 , ADAR2 , or both . A . Distributions of mRNA expression of ADAR1 and ADAR2 under ADAR KD and control conditions . Expression levels were quantified as transcripts per million ( TPM ) . B . Mean editing levels of testable sites in five comparisons between ADAR KD conditions or control experiment . Sites with significant editing differences between conditions are colored red , while gray represents nondifferential sites . Y = x line shown in blue . C . Proportions of lung cancer E - M differential sites that were also differential in ADAR KD conditions ( compared to controls ) . sigADAR1 : sites that were differential only in ADAR1 KD . sigADAR2 : sites that were differential only in ADAR2 KD . sigBoth : sites that were differential in both ADAR1 KD and (cid:36)(cid:39)(cid:36)(cid:53)(cid:21)(cid:3)(cid:46)(cid:39)(cid:15)(cid:3)(cid:82)(cid:85)(cid:3)(cid:76)(cid:81)(cid:3)(cid:71)(cid:82)(cid:88)(cid:69)(cid:79)(cid:72)(cid:3)(cid:46)(cid:39)(cid:17)(cid:3)(cid:55)(cid:75)(cid:72)(cid:3)(cid:83)(cid:85)(cid:72)(cid:73)(cid:76)(cid:91)(cid:3)(cid:182)(cid:85)(cid:72)(cid:71)(cid:183)(cid:3)(cid:76)(cid:81)(cid:71)(cid:76)(cid:70)(cid:68)(cid:87)(cid:72)(cid:86)(cid:3)(cid:85)(cid:72)(cid:71)(cid:88)(cid:70)(cid:72)(cid:71)(cid:3)(cid:72)(cid:71)(cid:76)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:79)(cid:72)(cid:89)(cid:72)(cid:79)(cid:3)(cid:69)(cid:92)(cid:3)(cid:68)(cid:87)(cid:3)(cid:79)(cid:72)(cid:68)(cid:86)(cid:87)(cid:3)(cid:19)(cid:17)(cid:19)(cid:24)(cid:3)(cid:88)(cid:83)(cid:82)(cid:81)(cid:3)(cid:46)(cid:39)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:70)(cid:82)(cid:81)(cid:87)(cid:85)(cid:82)(cid:79)(cid:15)(cid:3) (cid:69)(cid:88)(cid:87)(cid:3)(cid:71)(cid:76)(cid:71)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:83)(cid:68)(cid:86)(cid:86)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:87)(cid:68)(cid:87)(cid:76)(cid:86)(cid:87)(cid:76)(cid:70)(cid:68)(cid:79)(cid:3)(cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:81)(cid:70)(cid:72)(cid:3)(cid:85)(cid:72)(cid:84)(cid:88)(cid:76)(cid:85)(cid:72)(cid:80)(cid:72)(cid:81)(cid:87)(cid:17)(cid:3)(cid:182)(cid:53)(cid:72)(cid:80)(cid:68)(cid:76)(cid:81)(cid:183)(cid:29)(cid:3)(cid:72)(cid:71)(cid:76)(cid:87)(cid:76)(cid:81)(cid:74)(cid:3)(cid:86)(cid:76)(cid:87)(cid:72)(cid:86)(cid:3)(cid:87)(cid:75)(cid:68)(cid:87)(cid:3)(cid:90)(cid:72)(cid:85)(cid:72)(cid:3)(cid:81)(cid:82)(cid:87)(cid:3)(cid:86)(cid:76)(cid:74)(cid:81)(cid:76)(cid:73)(cid:76)(cid:70)(cid:68)(cid:81)(cid:87)(cid:79)(cid:92)(cid:3)(cid:71)(cid:76)(cid:73)(cid:73)(cid:72)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3)(cid:82)(cid:85)(cid:3) reduced across any comparison . * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * ADAR1 ADAR2 BRCA LUAD LUSC PRAD OV KIRC HNSC BRCA LUAD LUSC PRAD OV KIRC HNSC 0 5 10 15 0 100 200 300 F PK M condition E M Fig . S7 . Expression of ADARs in E and M tumors . Distributions of mRNA expression of ADAR1 ( left ) and ADAR2 ( right ) in E and M tumors across cancer types . Expression values , measured as Fragments Per Kilobase per Million mapped reads ( FPKM ) , were compared by Mann Whitney U tests , and significance of p - values are shown . * * p ≤ 0 . 01 ; * * * p ≤ 0 . 001 ; * * * * p ≤ 0 . 0001 . 0102030 0 5 10 024 0102030 051015 024 A B C D S M I npu t I L F 3 I P 1 I L F 3 I P 2 0 20 40 60 80 PKR 8075 N o r m a li z ed F o l d C hange ( aga i n s t 18 s ) S M I npu t I L F 3 I P 1 I L F 3 I P 2 0 2 4 6 8 10 PKR 8034 N o r m a li z ed F o l d C hange ( aga i n s t 18 s ) S M I npu t I L F 3 I P 1 I L F 3 I P 2 0 5 10 15 PKR 7702 N o r m a li z ed F o l d C hange ( aga i n s t 18 s ) * * * * * * * * * * ILF3 IP1 ILF3 IP2 SMInput ILF3 IP1 ILF3 IP2 SMInput HepG2 K562 0 25 50 75 100 −10 −5 0 5 10 Distance ( kb ) E d i t i ng s i t e s pe r k b K562 p = 1 . 32e−20 n = 86 0 100 200 300 −10 −5 0 5 10 Distance ( kb ) E d i t i ng s i t e s pe r k b HepG2 p = 8 . 29e−19 n = 96 siControl siADAR1 siADAR2 PKR 7702 PKR 7670 & 7666 PKR 8075 PKR 8082 PKR 8097 PKR 8034 E 32 % 36 % 46 % 45 % 32 % 20 % 32 % 0 % 4 % 0 % 0 % 0 % 0 % 0 % 29 % 31 % 32 % 45 % 32 % 18 % 31 % Fig . S8 . ILF3 binds closely to the differential editing sites in editing - expression correlated genes . A . Histogram of distances between differential editing sites in editing - correlated genes and the closest ILF3 eCLIP peaks in HepG2 and K562 cells ( turquoise ) , up to 10 kb . Gray curves represent distances for 10 sets of randomly picked A’s in the same genes as differential editing sites . Number of differential editing sites is given by n for each cell line . P - value was calculated by comparing the area under the curve ( AUC ) of the distance distribution for differential editing sites to a normal distribution fit to the AUC values of 10 , 000 sets of random gene - matched A’s . B . Normalized mCherry expression for nonedited or edited versions of sites in the 3’UTR of PKR in A549 cells . Five biological replicates were performed . Normalized expression values were compared between edited and nonedited versions by two - sided t - test . * * p < 0 . 01 . C . Editing levels of PKR 3’UTR editing sites in siControl , siADAR1 and siADAR2 A549 cells measured by Sanger sequencing . The peak signals of A and G nucleotides were measured by 4Peaks for editing level calculation ( G / ( A + G ) ) . The editing level of each editing site ( underlined ) is shown in the graph . D . Read coverage of ILF3 eCLIP - seq in HepG2 and K562 cells for two biological replicates ( ILF3 IP1 and ILF3 IP2 , turquoise ) and size - matched input ( SMInput , gray ) in each cell line . The five validated 3’ UTR editing sites affecting PKR mRNA abundance in A549 cells are labeled in magenta . E . Validation of PKR eCLIP signal overlapping three editing sites . PKR expression was measured by qRT - PCR in the IP or SMInput samples and normalized against the expression of 18s rRNA . Three technical replicates were performed ( other than two replicates for 8034 ) . P - value calculated by t - test . * p < 0 . 05 , * * p < 0 . 01 , * * * * p < 0 . 0001 . PK R W T PK R 7702 G 0 . 0 0 . 5 1 . 0 1 . 5 N o r m a li z ed m C he rr y E x p r e ss i on * * PK R W T PK R 8034 G 0 . 0 0 . 5 1 . 0 1 . 5 2 . 0 2 . 5 N o r m a li z ed m C he rr y E x p r e ss i on PK R W T PK R 8075 G 0 . 0 0 . 5 1 . 0 1 . 5 2 . 0 N o r m a li z ed m C he rr y E x p r e ss i on * * * * β - Actin E - Cadherin Vimentin γ - Catenin ADAR1 p110 isoform p150 isoform 43 KD 130 KD 180 KD 95 KD 55 KD 130 KD 180 KD 95 KD 130 KD 180 KD 95 KD 72 KD 34 KD 26 KD 17 KD 43 KD 55 KD 34 KD 26 KD 17 KD 72 KD siControl siADAR1 siADAR1 β - Actin 43 KD 55 KD 34 KD 26 KD 17 KD siControl siADAR1 siADAR1 siControl siADAR1 siADAR1 Blot1 Blot2 Blot3 Fig . S9 . Uncropped western blot images for Figure 4A . The original blots were cut to incubate with different antibodies and imaged separately . The images from the same blot were grouped by the large blue rectangles . siControl siADAR2 A549 siControl siADAR1 HMLE ADAR2 β - Actin E - Cadherin Vimentin γ - Catenin 43 KD 130 KD 180 KD 95 KD 55 KD 130 KD 180 KD 95 KD 130 KD 180 KD 95 KD 72 KD 34 KD 26 KD 43 KD 55 KD 34 KD 26 KD 17 KD 72 KD 72 KD 55 KD 72 KD Fig . S10 . Uncropped western blot images for Figure 4B . The original blots were cut to incubate with different antibodies and imaged separately . The images from the same blot were grouped by the large blue rectangles . β - Actin ADAR1 43 KD 55 KD 34 KD 26 KD siControl siADAR2 A549 siControl siADAR1 HMLE siControl siADAR2 A549 siControl siADAR1 HMLE 43 KD 34 KD 26 KD 17 KD β - Actin N - Cadherin siControl siADAR2 A549 siControl siADAR1 HMLE 130 KD 180 KD 95 KD 72 KD Blot1 Blot2 Blot3 Blot4 Fig . S11 . Uncropped western blot images for Figure 4C . The original blots were cut to incubate with different antibodies and imaged separately . The images from the same blot were grouped by the large blue rectangles . siADAR1 siADAR2 siControl β - Actin E - Cadherin Vimentin γ - Catenin ADAR1 ADAR2 43 KD 130 KD 180 KD 95 KD 55 KD 130 KD 180 KD 95 KD 130 KD 180 KD 95 KD 34 KD 26 KD 43 KD 55 KD 34 KD 26 KD 72 KD 72 KD 130 KD 180 KD 95 KD 72 KD 43 KD 55 KD 34 KD 26 KD β - Actin 43 KD 55 KD 34 KD 26 KD β - Actin siADAR1 siADAR2 siControl siADAR1 siADAR2 siControl siADAR1 siADAR2 siControl Blot1 Blot2 Blot3 Blot4 Fig . S12 . Uncropped western blot images for Figure 7A . Two different shRNAs were used to generated the ILF3 KD A549 cells . The frist shRNA ( highlighted in red ) was more effective than the second shRNA and was used for the reporter assays in this study . The original blots were cut to incubate with different antibodies and imaged separately . The images from the same blot were grouped by the large blue rectangle . s h C t r l s h I L F 3 w i t h e ff e c t i v e s h R N A 1 s h I L F 3 w i t h i n e ff e c t i v e s h R N A 2 β - Actin ILF3 43 KD 55 KD 130 KD 180 KD 95 KD 72 KD 34 KD 26 KD s h C t r l s h I L F 3 w i t h e ff e c t i v e s h R N A 1 s h C t r l PKR ILF3 siControl siILF3 _ 1 siILF3 _ 2 (cid:1115)(cid:16)(cid:36)(cid:70)(cid:87)(cid:76)(cid:81) (cid:40)(cid:16)(cid:38)(cid:68)(cid:71)(cid:75)(cid:72)(cid:85)(cid:76)(cid:81) (cid:49)(cid:16)(cid:38)(cid:68)(cid:71)(cid:75)(cid:72)(cid:85)(cid:76)(cid:81) ILF3 43 KD 130 KD 180 KD 95 KD 55 KD 130 KD 180 KD 95 KD 130 KD 180 KD 95 KD 72 KD 34 KD 26 KD 43 KD 34 KD 26 KD 72 KD Fig . S13 . Uncropped western blot images for Figure 7D . (cid:55)(cid:75)(cid:72)(cid:3)(cid:82)(cid:85)(cid:76)(cid:74)(cid:76)(cid:81)(cid:68)(cid:79)(cid:3)(cid:69)(cid:79)(cid:82)(cid:87)(cid:86)(cid:3)(cid:90)(cid:72)(cid:85)(cid:72)(cid:3)(cid:70)(cid:88)(cid:87)(cid:3)(cid:87)(cid:82)(cid:3)(cid:76)(cid:81)(cid:70)(cid:88)(cid:69)(cid:68)(cid:87)(cid:72)(cid:3)(cid:90)(cid:76)(cid:87)(cid:75)(cid:3)(cid:71)(cid:76)(cid:73)(cid:73)(cid:72)(cid:85)(cid:72)(cid:81)(cid:87)(cid:3) (cid:68)(cid:81)(cid:87)(cid:76)(cid:69)(cid:82)(cid:71)(cid:76)(cid:72)(cid:86)(cid:3)(cid:68)(cid:81)(cid:71)(cid:3)(cid:76)(cid:80)(cid:68)(cid:74)(cid:72)(cid:71)(cid:3)(cid:86)(cid:72)(cid:83)(cid:68)(cid:85)(cid:68)(cid:87)(cid:72)(cid:79)(cid:92)(cid:17)(cid:3)(cid:55)(cid:75)(cid:72)(cid:3)(cid:76)(cid:80)(cid:68)(cid:74)(cid:72)(cid:86)(cid:3)(cid:73)(cid:85)(cid:82)(cid:80)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:86)(cid:68)(cid:80)(cid:72)(cid:3)(cid:69)(cid:79)(cid:82)(cid:87)(cid:3)(cid:90)(cid:72)(cid:85)(cid:72)(cid:3)(cid:74)(cid:85)(cid:82)(cid:88)(cid:83)(cid:72)(cid:71)(cid:3)(cid:69)(cid:92)(cid:3)(cid:87)(cid:75)(cid:72)(cid:3)(cid:79)(cid:68)(cid:85)(cid:74)(cid:72)(cid:3)(cid:69)(cid:79)(cid:88)(cid:72)(cid:3)(cid:85)(cid:72)(cid:70)(cid:87)(cid:68)(cid:81)(cid:74)(cid:79)(cid:72)(cid:86)(cid:17) (cid:1115)(cid:16)(cid:36)(cid:70)(cid:87)(cid:76)(cid:81) 55 KD 43 KD 34 KD 26 KD (cid:57)(cid:76)(cid:80)(cid:72)(cid:81)(cid:87)(cid:76)(cid:81) 43 KD 55 KD 72 KD 34 KD 26 KD PKR 130 KD 180 KD 95 KD 72 KD 55 KD siControl siILF3 _ 1 siILF3 _ 2 siControl siILF3 _ 1 siILF3 _ 2 siControl siILF3 _ 1 siILF3 _ 2 Blot1 Blot2 Blot3 Blot4